New preprint: Deciphering bedaquiline and clofazimine resistance in tuberculosis Philip Fowler, 22nd March 202122nd March 2021 In this preprint we examine 14,151 clinical isolates drawn from the CRyPTIC dataset. Each isolate had its minimum inhibitory concentration (MIC) to bedaquiline and clofazimine measured and hence we were able to identify the transcription regulator Rv0678, as the current main source of elevated MICs to both these drugs. Lindsay Sonnenkalb, who is studying for her PhD with Stefan Niemann, then evolved Mycobacterium tuberculosis strains under sub-lethal concentrations of both compounds and was able to identify 189 different Rv0678 genetic variants that confer elevated MICs to bedaquiline and clofazimine. Detailed modelling of the protein structure allowed us to posit four main resistance mechanisms: impairment of DNA binding, reduction in protein stability, disruption of protein dimerization, and reduction in affinity for its fatty acid ligand. Share this:Twitter Related antimicrobial resistance clinical microbiology publication
antimicrobial resistance New publication: Assessing Drug Susceptibility in Tuberculosis 28th September 201829th September 2018 A paper was published in the New England Journal of Medicine earlier this week by… Share this:Twitter Read More
publication New Publication: Effect of SAO mutation on Band 3 12th January 201729th September 2018 There is a lovely story behind this paper just published earlier this week in Biochemistry…. Share this:Twitter Read More
antimicrobial resistance New Publication: Predicting whether mutations confer resistance to an antibiotic 5th January 201829th September 2018 Due to the rise of antibiotic resistance, it is increasingly important that your clinician knows… Share this:Twitter Read More